Contract Services - December 15, 2020
Recipharm invests USD 2.5 million in clinical GMP capacity
Recipharm, has announced an investment and capacity expansion at its facility in Israel. This investment will support customers’ growing demand for cGMP clinical supply of active pharma ingredients (API) and intermediates and is part of an integrated plan to enhance Recipharm’s offering in drug substances services, the company states. Fully operative by the end of […]
Business article - October 8, 2020
Brick by brick – The Recipharm journey
2020 is the year Recipharm celebrates 25 years of CDMO business. Chief Executive Officer and co-founder, Thomas Eldered looks back upon milestones, crucial turning points and the company’s goal of simplifying a product’s journey to market. The journey of Recipharm began in 1995 with the buyout of a solid dose facility in Stockholm, performed by […]
COVID-19 - April 28, 2020
Recipharm’s Erdosteine to be tested as part of COVID-19 treatment
Recipharm’s molecule Erdosteine will be tested in a clinical study as an add-on treatment for COVID-19 patients. The clinical study, which began on 7th April, is being conducted in clinical centres actively involved in COVID-19 treatment in Milan and Bergamo. Both Milan and Bergamo are based in Lombardy, the Italian region most affected by the virus. […]
Agreement - December 19, 2019
Recipharm partners with Aptahem
Recipharm has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate. The aptamer-based drug candidate is intended to treat life-threatening condition sepsis, a potentially fatal condition which involves a general inflammatory response, known as systemic inflammatory response syndrome (SIRS), caused by an infection. Recipharm will develop an injectable formulation for the upcoming […]
CDMO - December 10, 2019
Recipharm invests in its US inhalation development service
Recipharm has invested USD 450,000 into its Research Triangle Park (RTP), North Carolina, US facility to install a SprayVIEW system that will support inhalation and nasal product development. The newly acquired system was installed alongside an environmental controlled aerosol collection chamber for inhalation testing and a metered dose inhaler (MDI) and dry powder inhaler (DPI) […]
Acquisition - November 18, 2019
Recipharm offers to acquire Consort Medical
Recipharm and Consort Medical have reached an agreement on the terms of a recommended cash offer by Recipharm Holdings Limited, a wholly-owned direct subsidiary of Recipharm, for Consort. The Board of Consort has confirmed its unanimous intention to recommend a cash offer for an equity value of GBP 505 million (approximately SEK 6,284 million). Consort […]
